A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The study consists of 2 parts: Part A is a randomized, multiple-dose, double-blind,
placebo-controlled sequential dose escalation study to evaluate GS-6624 in subjects with
Idiopathic Pulmonary Fibrosis (IPF) and was completed in October 2011.
Part B is a randomized, two-dose, open-label dose expansion study to evaluate GS-6624 in
subjects with IPF and is currently enrolling.